keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic cancer

keyword
https://www.readbyqxmd.com/read/29784257/patient-empowerment-reduces-pain-in-geriatric-patients-after-gynecologic-onco-surgery-subgroup-analysis-of-a-prospective-randomized-controlled-clinical-trial
#1
Anna-Maria Collette, Claudia Spies, Rahel Eckardt, Klaus-Dieter Wernecke, Maren Schmidt
PURPOSE: This study aimed to determine the effect of patient empowerment on acute postoperative pain. This research was part of the Patient Empowerment and Risk-Assessed Treatment to Improve Outcome in the Elderly After Onco-Surgery Trial. DESIGN: This research was a prospective randomized controlled interventional study. METHODS: Patients who underwent gynecologic onco-surgery were included in this analysis of demographic data, basic characteristics, pain intensity by numeric rating scale, and mode of pain therapy...
June 2018: Journal of Perianesthesia Nursing: Official Journal of the American Society of PeriAnesthesia Nurses
https://www.readbyqxmd.com/read/29783721/azd1775-increases-sensitivity-to-olaparib-and-gemcitabine-in-cancer-cells-with-p53-mutations
#2
Xiangbing Meng, Jianling Bi, Yujun Li, Shujie Yang, Yuping Zhang, Mary Li, Haitao Liu, Yiyang Li, Megan E Mcdonald, Kristina W Thiel, Kuo-Kuang Wen, Xinhao Wang, Meng Wu, Kimberly K Leslie
Tumor suppressor p53 is responsible for enforcing cell cycle checkpoints at G1/S and G2/M in response to DNA damage, thereby allowing both normal and tumor cells to repair DNA before entering S and M. However, tumor cells with absent or mutated p53 are able to activate alternative signaling pathways that maintain the G2/M checkpoint, which becomes uniquely critical for the survival of such tumor cells. We hypothesized that abrogation of the G2 checkpoint might preferentially sensitize p53-defective tumor cells to DNA-damaging agents and spare normal cells with intact p53 function...
May 19, 2018: Cancers
https://www.readbyqxmd.com/read/29781537/microrna-508-suppresses-epithelial-mesenchymal-transition-migration-and-invasion-of-ovarian-cancer-cells-through-the-mapk1-erk-signaling-pathway
#3
Lan Hong, Yifeng Wang, Wangsheng Chen, Shuying Yang
Ovarian cancer (OC) is the sixth most common cancer in women worldwide. Despite advances in detection and therapies, it still represents the most lethal gynecologic malignancy in the industrialized countries. Unfortunately, the molecular events that lead to the development of this highly aggressive disease remain largely unknown. The study explored the ability of microRNA-508 (miR-508) to influence proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in OC cells. We quantified the level of miR-508 cancer tissues with corresponding adjacent normal tissues collected from 84 patients with OC...
May 21, 2018: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29780815/endometriosis-malignant-transformation-epigenetics-as-a-probable-mechanism-in-ovarian-tumorigenesis
#4
REVIEW
Jiaxing He, Weiqin Chang, Chunyang Feng, Manhua Cui, Tianmin Xu
Endometriosis, defined as the presence of ectopic endometrial glands and stroma outside the uterine cavity, is a chronic, hormone-dependent gynecologic disease affecting millions of women across the world, with symptoms including chronic pelvic pain, dysmenorrhea, dyspareunia, dysuria, and subfertility. In addition, there is well-established evidence that, although endometriosis is considered benign, it is associated with an increased risk of malignant transformation, with the involvement of various mechanisms of development...
2018: International Journal of Genomics
https://www.readbyqxmd.com/read/29780254/are-ovarian-cancer-stem-cells-the-target-for-innovative-immunotherapy
#5
REVIEW
Liang Wang, Tianmin Xu, Manhua Cui
Cancer stem cells (CSCs), a subpopulation of cancer cells with the ability of self-renewal and differentiation, are believed to be responsible for tumor generation, progression, metastasis, and relapse. Ovarian cancer, the most malignant gynecological cancer, has consistent pathology behavior with CSC model, which suggests that therapies based on ovarian cancer stem cells (OCSCs) can gain a more successful prognosis. Much evidence has proved that epigenetic mechanism played an important role in tumor formation and sustainment...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29779470/ascites-derived-extracellular-micrornas-as-potential-biomarkers-for-ovarian-cancer
#6
Luděk Záveský, Eva Jandáková, Vít Weinberger, Luboš Minář, Veronika Hanzíková, Daniela Dušková, Lenka Záveská Drábková, Iveta Svobodová, Aleš Hořínek
Ovarian cancer as the most fatal gynecological malignancy is often manifested by excessive fluid accumulation known as ascites or effusion. Ascites-derived microRNAs (miRNAs) may be closely associated with ovarian cancer progression. However, our knowledge of their roles, altered expression, and clinical outcomes remained limited. In this study, large-scale expression profiling of 754 human miRNAs was performed using real-time quantitative polymerase chain reaction and 384-well TaqMan array human miRNA A and B cards to identify differentially expressed miRNAs between extracellular fraction of the ascitic fluid associated with high-grade serous ovarian carcinomas and control plasma...
January 1, 2018: Reproductive Sciences
https://www.readbyqxmd.com/read/29778506/quality-of-life-symptoms-and-care-needs-in-patients-with-persistent-or-recurrent-platinum-resistant-ovarian-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#7
Vivian E von Gruenigen, Helen Q Huang, David Cella, MichaelA Zevon, Jason A LaChance, Joan L Walker, Ritu Salani, Susan C Modesitt, Robert T Morris, William H Bradley, Matthew P Boente, Lari Wenzel
OBJECTIVES: The goals of treating recurrent platinum-resistant ovarian cancer are palliative, aimed at reducing symptoms and improving progression free survival. A prospective trial was conducted to determine the prevalence and severity of symptoms, and associated care needs. METHODS: Eligible women included those with persistent or recurrent platinum-resistant ovarian cancer with an estimated life expectancy of at least 6 months. The Needs at the End-of-Life Screening Tool (NEST), FACIT-Fatigue (FACIT-F), NCCN-FACT Ovarian Symptom Index [NFOSI-18]; Disease Related Symptoms (DRS), Treatment Side Effects (TSE), and Function/Well Being (F/WB) were collected at study entry, 3 and 6 months...
May 17, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29777795/sirna-in-ovarian-cancer-delivery-strategies-and-targets-for-therapy
#8
REVIEW
Dirk van den Brand, Vicky Mertens, Leon F A G Massuger, Roland Brock
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, and the sixth leading cause of cancer related death in women overall. Despite improved surgical techniques and advances in chemotherapy, mortality hardly decreased over the last twenty years. The major problem is that (micro)metastases persevere in the abdominal cavity, causing incurable tumor recurrence. Therefore, there is an imminent need for new therapeutic strategies. Oligonucleotide (ON) based therapies such as RNA interference (RNAi) provide the possibility to specifically address disease-related pathways...
May 16, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29777595/a-ring-based-compensator-imrt-system-optimized-for-low-and-middle-income-countries-design-and-treatment-planning-study
#9
Jonathon Van Schelt, Daniel Smith, Nicholas Fong, Dolla Toomeh, Patricia A Sponseller, Derek W Brown, Meghan W Macomber, Nina A Mayr, Shilpen Patel, Adam Shulman, G V Subrahmanyam, K Govindarajan, Eric C Ford
PURPOSE: We propose a novel compensator-based IMRT system designed to provide a simple, reliable, and cost-effective adjunct technology, with the goal of expanding global access to advanced radiotherapy techniques. The system would employ easily-reusable tungsten bead compensators that operate independent of a gantry (e.g. mounted in a ring around the patient). Thereby the system can be retrofitted to existing linac and cobalt teletherapy units. This study explores the quality of treatment plans from the proposed system and the dependence on associated design parameters...
May 19, 2018: Medical Physics
https://www.readbyqxmd.com/read/29776873/effects-of-reflexology-and-progressive-muscle-relaxation-on-pain-fatigue-and-quality-of-life-during-chemotherapy-in-gynecologic-cancer-patients
#10
Hacer Alan Dikmen, Fusun Terzioglu
Our aim was to investigate the effect of reflexology and progressive muscle relaxation (PMR) exercises on pain, fatigue, and quality of life (QoL) of gynecologic cancer patients during chemotherapy. Eighty participants were randomly assigned to one of four groups: reflexology, progressive muscle relaxation (PMR) exercises, both (reflexology + PMR), or a control group. Data were collected with a general data collection form, Brief Pain and Fatigue inventories, and Multidimensional Quality-of-Life Scale-Cancer...
May 15, 2018: Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses
https://www.readbyqxmd.com/read/29776639/gynecologic-cancers-molecular-updates-2018
#11
REVIEW
Eman Abdulfatah, Quratulain Ahmed, Baraa Alosh, Sudeshna Bandyopadhyay, Martin H Bluth, Rouba Ali-Fehmi
Ovarian carcinoma continues to be a concern for woman and maintains significant morbidity and mortality. Emerging molecular markers are providing additional opportunities for effective diagnosis and prognosis of disease. An integrated clinicopathologic and molecular classification of gynecologic malignancies has the potential to refine the clinical risk prediction of patients with cancer and to provide more tailored treatment recommendations.
June 2018: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/29775688/gyneco-oncological-genomics-and-emerging-biomarkers-for-cancer-treatment-with-immune-checkpoint-inhibitors
#12
REVIEW
Giuseppe Curigliano
In gynecological cancers tumor infiltrating lymphocytes and upregulation of immune-related gene signatures have been associated with a better prognosis. Knowledge of tumor immunogenicity and associated gene signatures suggests that the tumor immune landscape is a key determinant to define patient prognosis and potentially to predict response to immune-checkpoint inhibitors. The aim of this review is to give an overview of immune gene signatures across gynecology histological cancer types, defining their prognostic and potential predictive role...
May 15, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29774521/patient-reported-outcomes-of-multiple-myeloma-patients-treated-with-panobinostat-after-%C3%A2-2-lines-of-therapy-based-on-the-international-phase-3-randomized-double-blind-placebo-controlled-panorama-1-trial
#13
Paul G Richardson, Robert L Schlossman, Anuja N Roy, Ashok Panneerselvam, Suddhasatta Acharyya, Monika Sopala, Sagar Lonial
The phase 3 PANORAMA-1 trial led to regulatory approvals of panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma after ≥2 prior regimens, including BTZ and an immunomodulatory drug. Patient-reported outcomes (PROs) were assessed in PANORAMA-1, with data available for 73 patients in the PAN + BTZ + DEX arm and 74 patients in the placebo (PBO) + BTZ + DEX arm. Per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), global health status/quality of life (QoL) scores initially declined with PAN + BTZ + DEX during the first 24 weeks before approaching baseline scores and remaining steady during the next 24 weeks, with no difference between arms at Week 48...
May 17, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29773661/phase-i-study-of-oncolytic-vaccinia-virus-gl-onc1-in-patients-with-peritoneal-carcinomatosis
#14
Ulrich M Lauer, Martina Schell, Julia Beil, Susanne Berchtold, Ursula Koppenhöfer, Jörg Glatzle, Alfred Königsrainer, Robert Möhle, Dominik Nann, Falko Fend, Christina Pfannenberg, Michael Bitzer, Nisar P Malek
OBJECTIVE: Peritoneal carcinomatosis (PC) is common in advanced tumor stages or disease recurrence arising from gastrointestinal cancers, gynecologic malignancies, or primary peritoneal carcinoma. Since current therapies are mostly ineffective, new thera-peutic approaches are needed. Here, we report on a phase I study designed to assess safety, MTD, and anti-tumor activity of intra-peri-toneal (i.p.) administration of oncolytic vaccinia virus GL-ONC1 in advanced stage PC patients. DESIGN: GL-ONC1 was administered i...
May 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29773331/novel-use-of-viewray-mri-guidance-for-high-dose-rate-brachytherapy-in-the-treatment-of-cervical-cancer
#15
Huaising C Ko, Jessie Y Huang, Jessica R Miller, Rupak K Das, Charles R Wallace, Anna-Maria A De Costa, David M Francis, Margaret R Straub, Bethany M Anderson, Kristin A Bradley
PURPOSE: To characterize image quality and feasibility of using ViewRay MRI (VR)-guided brachytherapy planning for cervical cancer. METHODS AND MATERIALS: Cervical cancer patients receiving intracavitary brachytherapy with tandem and ovoids, planned using 0.35T VR MRI at our institution, were included in this series. The high-risk clinical target volume (HR-CTV), visible gross tumor volume, bladder, sigmoid, bowel, and rectum contours for each fraction of brachytherapy were evaluated for dosimetric parameters...
May 14, 2018: Brachytherapy
https://www.readbyqxmd.com/read/29770632/impact-of-increased-utilization-of-neoadjuvant-chemotherapy-on-survival-in-patients-with-advanced-ovarian-cancer-experience-from-a-comprehensive-cancer-center
#16
Yong Jae Lee, Young Shin Chung, Jung Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim
OBJECTIVE: The choice between primary debulking surgery (PDS) and neoadjuvant chemotherapy (NAC) in advanced ovarian cancer remains controversial. We evaluated NAC use in our center before and after results from a randomized trial were published, with the aim to determine the impact of changes in the neoadjuvant strategy on survival in advanced-stage ovarian cancer. METHODS: We retrospectively investigated the clinical course of 435 patients with ovarian, tubal, or peritoneal carcinoma (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV)...
April 18, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29770630/survival-impact-of-low-anterior-resection-in-patients-with-epithelial-ovarian-cancer-grossly-confined-to-the-pelvic-cavity-a-korean-multicenter-study
#17
Miseon Kim, Dong Hoon Suh, Jeong Yeol Park, E Sun Paik, Seungmee Lee, Kyung Jin Eoh, Joo Hyun Nam, Yoo Young Lee, Jae Weon Kim, Sunghoon Kim
OBJECTIVE: To evaluate survival impact of low anterior resection (LAR) in patients with epithelial ovarian cancer (EOC) grossly confined to the pelvis. METHODS: We retrospectively reviewed 397 patients who underwent primary staging surgery for treatment of 2014 International Federation of Gynecology and Obstetrics (FIGO) stage II-IIIA EOC: 116 (29.2%) IIA, 212 (53.4%) IIB, and 69 (17.4%) IIIA. Patients with grossly enlarged retroperitoneal lymph nodes positive for metastatic carcinoma were excluded...
April 13, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29770626/practice-guidelines-for-management-of-ovarian-cancer-in-korea-a-korean-society-of-gynecologic-oncology-consensus-statement
#18
REVIEW
Dong Hoon Suh, Suk Joon Chang, Taejong Song, Sanghoon Lee, Woo Dae Kang, Sun Joo Lee, Ju Won Roh, Won Duk Joo, Joo Hee Yoon, Dae Hoon Jeong, Hee Seung Kim, Sung Jong Lee, Yong Il Ji, Hyun Jung Kim, Jeong Won Lee, Jae Weon Kim, Duk Soo Bae
Since after 2006 when the first edition of practice guidelines for gynecologic oncologic cancer treatment was released, the Korean Society of Gynecologic Oncology (KSGO) has published the following editions on a regular basis to suggest the best possible standard care considering updated scientific evidence as well as medical environment including insurance coverage. The Guidelines Revision Committee was summoned to revise the second edition of KSGO practice guidelines, which was published in July 2010, and develop the third edition...
March 10, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29770619/impact-of-lymph-node-ratio-on-survival-in-stage-iiic-endometrioid-endometrial-cancer-a-turkish-gynecologic-oncology-group-study
#19
Ali Ayhan, Nazlı Topfedaisi Ozkan, Murat Öz, Günsu Kimyon Comert, Zeliha Firat Cuylan, Gonca Çoban, Osman Turkmen, Baki Erdem, Hanifi Şahin, Özgür Akbayır, Murat Dede, Ahmet Taner Turan, Husnu Celik, Tayfun Güngör, Ali Haberal, Macit Arvas, Mehmet Mutlu Meydanli
OBJECTIVE: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in women with stage IIIC endometrioid endometrial cancer (EC). METHODS: A multicenter, retrospective department database review was performed to identify patients with stage IIIC pure endometrioid EC at 6 gynecologic oncology centers in Turkey. A total of 207 women were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 2 groups: LNR1 (≤0...
March 13, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29770618/peritoneal-cancer-index-as-a-predictor-of-survival-in-advanced-stage-serous-epithelial-ovarian-cancer-a-prospective-study
#20
Alaa A Elzarkaa, Waleed Shaalan, Doaa Elemam, Hassan Mansour, Mahmoud Melis, Eduard Malik, Amr A Soliman
OBJECTIVE: A numerical score, the peritoneal cancer index (PCI), was developed to reflect the extent of tumor growth in gastric and colorectal cancers and to tailor treatment. This study aimed to examine the value of the PCI score in advanced epithelial ovarian cancer (EOC) regarding completeness of surgical cytoreduction and survival. METHODS: This was a prospective observational cohort study. Patients with primary serous EOC at International Federation of Gynecology and Obstetrics (FIGO) stages IIIB or higher were included...
March 8, 2018: Journal of Gynecologic Oncology
keyword
keyword
3314
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"